Sanofi Looks To Build On Dupixent Dominance With OX40L Drug

Amlitelimab Could Be Dosed Less Frequently

Sanofi
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

More from R&D